[Antitumoral activity of calusterone in advanced mammary carcinoma (author's transl)].
Thirty-one post-menopausal patients with advanced mammary carcinoma were treated with calusterone (7-beta, 17-alpha-dimethyl-testosterone), 200 mg daily per os for at least three months. Twenty-seven patients were avaluable. Eight patients (29%) had an objective response; two patients had a complete remission maintained for more than eighteen months by repeated three-month courses of therapy. In eight patients (29%), calusterone produced no objective response, without disease progression. The main side effects have been hirsutism, acne and gastro-intestinal distress; no libido modification was observed. Increased BSP retention was observed in one third of patients.
D000152:Acne Vulgaris / Q000139:chemically induced; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006628:Hirsutism / Q000139:chemically induced; D006801:Humans; D008777:Methyltestosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008875:Middle Aged; D012075:Remission, Spontaneous; D013997:Time Factors
D008777:Methyltestosterone
Attività antitumorale del calusterone nel carcinoma mammario avanzato